Caris Life Sciences and Flatiron Health team up to advance cancer research and care with real-world data initiative

Caris Life Sciences and Flatiron Health have joined forces to create a comprehensive real-world data (RWD) offering for cancer research. This collaboration combines Caris’ genomic, transcriptomic, and imaging database, built through its AI and machine learning algorithms, with Flatiron’s longitudinal patient data and clinical outcomes. Leveraging their respective expertise in molecular science and oncology-specific tools, Caris and Flatiron aim to provide researchers with robust RWD at scale, accelerating the development of personalized therapeutic interventions.

Caris Life Sciences, an AI TechBio company recognized for its contributions to precision medicine and molecular profiling, leverages AI and advanced algorithms to analyze its substantial RWD repository, exceeding 50 petabytes of data. This dataset features diverse data types, including genomic, transcriptomic, proteomic, and imaging information, establishing a valuable benchmark for the industry. Caris provides comprehensive molecular profiling through whole exome and whole transcriptome sequencing for each patient, aligning with their vision of using AI-powered precision medicine to improve health care, and advance patient care.

Flatiron Health, a health tech company and independent affiliate of Roche Group, contributes its expertise in translating real-world evidence (RWE) into practical insights to this collaboration. By combining its comprehensive longitudinal patient data and clinical outcomes with Caris’ molecular data, the partnership aims to contribute significantly to cancer therapeutics development. This will be achieved by providing valuable RWD to researchers, clinicians, and patient communities.

David Spetzler, President of Caris Life Sciences, stated, “We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma’s efforts to bring novel personalized therapeutic interventions to market to improve the lives of cancer patients.” He also underscored the capacity of the data union to enhance biological and clinical context, providing deeper insights into patient experiences.

Stephanie Reisinger, Senior Vice President and General Manager, Real-World Evidence at Flatiron Health, highlighted the potential of the partnership in creating a comprehensive clinical-omics dataset, saying, “This opportunity has the potential to create the largest and best-in-class clinical-omics dataset with Whole Exome and Whole Transcriptome sequencing coverage, expanding our opportunity to support biopharma in the preclinical stages of drug discovery and translation.”

Brian Lamon, Chief Business Officer of Caris Life Sciences, emphasized the importance of addressing the challenge of building cohorts for research in oncology, and the potential of the collaboration to fuel drug discovery and therapeutic innovation.

This strategic collaboration between Caris Life Sciences and Flatiron Health is poised to drive advancements in cancer research, optimize drug discovery, and enhance patient care through the creation of a robust and diverse multimodal dataset.